86541-78-8

86541-78-8 structure

Name: benazeprilat
Chemical Name: benazeprilat
CAS Number: 86541-78-8
Molecular Formula: C₂₂H₂₄N₂O₅
Molecular Weight: 396.43600
Catalog: Signaling Pathways Metabolic Enzyme/Protease Angiotensin-converting Enzyme (ACE)
Create Date: 2018-03-06 08:00:00
Modify Date: 2024-01-03 22:29:46
Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monotherapy and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line treatment in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3].

Name	benazeprilat
Synonyms	1-carboxymethyl-3-1-carboxy-3-phenyl-(1S)-propylamino-2,3,4,5-tetrahydro-1H-(3S)-1-benzazepine-2-one Cibacen 3-[1-carboxy-3-phenyl-(1S)-propylamino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid Benazepril Related Compound C (50 mg) ((3S)-3-[[(1S)-1- carboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazepine]-1-acetic acid) benazeprilate (3S)-3-[[(S)-1-Carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid (3S)-3-[[(1S)-1-carboxy-3-phenylpropyl]aMino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine]-1-acetic acid 1H-1-Benzazepine-1-acetic acid,3-(1S)-1-carboxy-3-phenylpropylamino-2,3,4,5-tetrahydro-2-oxo-,(3S) Benazepril Related CoMpound C 1-carboxymethyl-3S-(1S-carboxy-3-phenylpropylamino)-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one

Description	Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monotherapy and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line treatment in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)
Target	Human Endogenous Metabolite
In Vivo	Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect[2]. Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI[3]. Animal Model: Male SHR (14-16 weeks of age, 250-350 g)[2]. Dosage: 10 mg/kg Administration: I.V; once a day for 2 days. Result: Produced hypotensive effect. Animal Model: Beagle dogs (12.0-19.5 kg)[3]. Dosage: 0.7 mg/kg Administration: P.O, once a day for 5 days. Result: Effected systemic RAAS peptides.
References	[1]. Barrios V, Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1653-71. [2]. Bazil MK, Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):405-11. [3]. Mochel JP, Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80.

Density	1.34 g/cm3
Boiling Point	711.3ºC at 760 mmHg
Melting Point	270-272ºC
Molecular Formula	C₂₂H₂₄N₂O₅
Molecular Weight	396.43600
Flash Point	384ºC
Exact Mass	396.16900
PSA	106.94000
LogP	2.55050
Index of Refraction	1.643